Syntex' Toradol Oral approved
Oral ketorolac tromethamine non-narcotic nonsteroidal anti- inflammatory drug approved by FDA "for limited duration use, as needed, for the management of pain," Syntex announces Dec. 20. Toradol Oral is not recommended for chronic use due to the incidence of adverse gastrointestinal events that increases with prolonged use, Syntex notes. Toradol Oral is expected to be available in March 1992, and Syntex "expects to have an agreement signed in the near future with a marketing partner." Toradol IM injectable, approved in May 1990, is comarketed in the U.S. by Roche. The oral ketorolac could be used as a followup therapy for patients who have received the injectable form of the drug.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth